Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Oliva Robert Letterio

2. Date of Event Requiring Statement (MM/DD/YYYY) 2/19/2021

3. Issuer Name and Ticker or Trading Symbol

Novo Integrated Sciences, Inc. [NVOS]

(Last) (First) (Middle)

C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100,

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

BELLEVUE,, WA 98004

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	178555	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy) ⁽¹⁾⁽²⁾	6/29/2015	6/29/2023	Common Stock	150000	$1.60	D
Stock Option (right to buy) ⁽²⁾	4/28/2017	4/28/2024	Common Stock	25000	$1.60	D
Stock Option (right to buy) ⁽²⁾	1/26/2021 ⁽³⁾	1/25/2026	Common Stock	19800 ⁽³⁾	$3.80	D

Explanation of Responses:
(1)	Information reported on this Form 3 has been adjusted to give effect to the 1-for-10 reverse stock split of the issuer's common stock, which was effective on February 1, 2021.
(2)	Represents a grant by the issuer, approved by the issuer's Board of Directors.
(3)	The grant vests, and becomes exercisable, with respect to 1,650 shares each month, beginning on the date of grant.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Oliva Robert Letterio C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE,, WA 98004	X

Signatures
/s/ Christopher David, as Attorney-in-Fact for Robert Oliva		2/19/2021
^**Signature of Reporting Person		Date